financetom
Business
financetom
/
Business
/
Palantir Seen Benefiting From AI Platform Strength, Defense Spending, Commercial Growth, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Palantir Seen Benefiting From AI Platform Strength, Defense Spending, Commercial Growth, Oppenheimer Says
Apr 30, 2026 11:11 AM

01:58 PM EDT, 04/30/2026 (MT Newswires) -- Palantir Technologies ( PLTR ) could benefit from a sticky AI software platform with high switching costs, rising government defense spending, expanding commercial adoption and valuation support, Oppenheimer said in a research note Thursday.

The company's customized ontology-based systems become difficult to replace once embedded in customer operations. The company continues to expand in commercial markets and its customer count rose to 780 in 2025 from 375 in 2023, the investment firm said.

Oppenheimer said US and allied military spending is shifting toward AI-enabled software. This supports Palantir's ( PLTR ) government opportunity. Government software and services spending is expected to grow to $666 billion by 2029 from $490 billion in 2025.

The firm said Palantir ( PLTR ) still has a long runway for commercial expansion which is supported by a $2.1 trillion addressable market by 2030. The company's premium valuation is supported by its government contracts, accelerating commercial growth and improving margins, according to the note.

Oppenheimer initiated coverage with an outperform rating and a $200 price target.

Price: 138.98, Change: +1.01, Percent Change: +0.73

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Checkpoint Therapeutics Says FDA Accepted Revised Biologics License Application for Cosibelimab
Checkpoint Therapeutics Says FDA Accepted Revised Biologics License Application for Cosibelimab
Jul 25, 2024
11:51 AM EDT, 07/25/2024 (MT Newswires) -- Checkpoint Therapeutics ( CKPT ) said Thursday that the US Food and Drug Administration has accepted for review its resubmission of the biologics license application for cosibelimab, with a Prescription Drug User Fee Act target date of Dec. 28. Cosibelimab is a potential treatment of advanced cutaneous squamous cell carcinoma, a type of...
Update: Bombardier Loses Nearly 4% as Its Q2 Adjusted Profit Rises 39%
Update: Bombardier Loses Nearly 4% as Its Q2 Adjusted Profit Rises 39%
Jul 25, 2024
11:46 AM EDT, 07/25/2024 (MT Newswires) -- Bombardier (BBD-B.TO) on Thursday said its second-quarter adjusted profit rose 39% as revenue rose by nearly a third, driven by higher aircraft deliveries and a steady increase in services revenue. The company said its second-quarter adjusted profit, excluding most one-time items. rose to US$111 million, or US$1.04 per share, up from US$0 million,...
Group 1 Auto to Offer $500 Million of Senior Unsecured Notes Due 2030
Group 1 Auto to Offer $500 Million of Senior Unsecured Notes Due 2030
Jul 25, 2024
11:44 AM EDT, 07/25/2024 (MT Newswires) -- Group 1 Automotive ( GPI ) early Thursday disclosed plans for a $500 million private placement of senior unsecured notes due 2030, subject to market conditions. The automotive retail chain expects to use the net proceeds from the upcoming offering to repay prior borrowings made through its revolving credit facility in addition to...
Hasbro Lifts Full-Year Core Profitability Outlook as Quarterly Results Beat Estimates
Hasbro Lifts Full-Year Core Profitability Outlook as Quarterly Results Beat Estimates
Jul 25, 2024
11:46 AM EDT, 07/25/2024 (MT Newswires) -- Hasbro ( HAS ) on Thursday increased its full-year outlook for core profitability as second-quarter results came in ahead of market expectations, aided by margin improvement. Adjusted earnings per share advanced to $1.22 for the three months ended June 30 from $0.49 last year and surpassed the $0.76 average analyst estimate on Capital...
Copyright 2023-2026 - www.financetom.com All Rights Reserved